Date: October 4, 2024
Attention: Providers
Effective date: October 10, 2024
Call to action: On September 25, 2024, Pfizer, the manufacturer voluntarily recalled all Oxbryta® (voxelotor) products from worldwide markets due to safety concerns.
Oxbryta will no longer be a covered benefit and will no longer be on the formulary starting October 17, 2024.
| Product | NDC No. |
| OXBRYTA 500 MG TABLET | 72786010101 |
| OXBRYTA 300 MG TABLET FOR SUSP | 72786011102 |
| OXBRYTA 300 MG TABLET FOR SUSP | 72786011103 |
| OXBRYTA 300 MG TABLET | 72786010202 |
| OXBRYTA 300 MG TABLET | 72786010203 |
Next step for Providers: Providers should inform their impacted patients and arrange for the return and replacement of the drug.
If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.